Balyasny Asset Management L.P. Has $438,000 Stock Holdings in Artivion, Inc. (NYSE:AORT)

Balyasny Asset Management L.P. trimmed its position in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 64.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,327 shares of the company's stock after selling 27,711 shares during the period. Balyasny Asset Management L.P.'s holdings in Artivion were worth $438,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC boosted its holdings in shares of Artivion by 236.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock worth $32,000 after buying an additional 786 shares during the period. R Squared Ltd acquired a new stake in Artivion during the fourth quarter worth approximately $39,000. Arcadia Investment Management Corp MI bought a new stake in shares of Artivion during the fourth quarter worth approximately $43,000. Venturi Wealth Management LLC bought a new stake in shares of Artivion during the fourth quarter worth approximately $78,000. Finally, KBC Group NV grew its position in shares of Artivion by 80.4% in the fourth quarter. KBC Group NV now owns 2,813 shares of the company's stock valued at $80,000 after purchasing an additional 1,254 shares during the last quarter. 86.37% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Jean F. Holloway sold 9,926 shares of the business's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $29.00, for a total transaction of $287,854.00. Following the completion of the transaction, the senior vice president now owns 187,258 shares of the company's stock, valued at approximately $5,430,482. The trade was a 5.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO James P. Mackin sold 42,156 shares of Artivion stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $1,151,280.36. Following the completion of the transaction, the chief executive officer now owns 663,882 shares in the company, valued at approximately $18,130,617.42. This represents a 5.97% decrease in their position. The disclosure for this sale can be found here. Insiders sold 111,273 shares of company stock worth $2,951,340 over the last three months. Insiders own 7.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on AORT. Citizens Jmp raised Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. JMP Securities reissued a "market outperform" rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, May 6th. Needham & Company LLC restated a "buy" rating and issued a $32.00 price target on shares of Artivion in a research note on Tuesday, May 6th. Finally, Stifel Nicolaus dropped their price objective on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research note on Tuesday, February 25th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Artivion has a consensus rating of "Buy" and an average price target of $31.40.

Artivion Price Performance

AORT stock traded down $0.30 during midday trading on Thursday, reaching $28.25. The company had a trading volume of 19,742 shares, compared to its average volume of 323,504. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $32.33. The stock has a 50 day moving average price of $24.96 and a 200-day moving average price of $27.35. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -1,417.50 and a beta of 1.54.

Artivion (NYSE:AORT - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.06). The firm had revenue of $98.98 million during the quarter, compared to analyst estimates of $94.81 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. Equities research analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.